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Objective - A double-blind, placebo-controlled multi-
center study involving 34 centers from different Brazilian
regions was performed to evaluate the antihypertensive
efficacy and tolerability of trandolapril, an angiotensin I
converting enzyme inhibitor, in the treatment of mild-to-
moderate systemic arterial hypertension.
Methods - Of 262 patients enrolled in this study, 127
were treated with trandolapril 2 mg/day for 8 consecutive
weeks, and the remaining 135 patients received placebo
for the same period of time. Reduction in blood pressure
(BP) and the occurrence of adverse events during this
period were evaluated in both groups.
Results - Significant reductions in both systolic and
diastolic pressures were observed in patients treated with
trandolapril when compared with those on placebo.
Antihypertensive efficacy was achieved in 57.5% of the
patients on trandolapril and in 42% of these normal values
of BP were obtained. The efficacy of trandolapril was simi-
lar in all centers, regardless of the area of the country. In a
subset of 30 patients who underwent ABPM, responders
showed a significant hypotensive effect to trandolapril
throughout the 24 hour day. The adverse event profile was
similar in both trandolapril and placebo groups.
Conclusion - Our results demonstrate, for the first
time in a large group of hypertensive patients from different
regions in Brazil, good efficacy and tolerability of trando-
lapril during treatment of mild-to-moderate essential sys-
temic hypertension.
Keywords: mild-to-moderate hypertension, trandolapril,
ACE inhibitor
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Trandolapril, a nonsulfidrylic compound, is one of the
newest members of the angiotensin I converting enzyme
inhibitor (ACEI) class. It is a prodrug and must be hydro-
lised to its active metabolite, trandolaprilate, to exert its
antihypertensive effect. One important characteristic of this
drug is its long-lasting biphasic half-life, ranging from 16 to
24 hours1, allowing a single dose therapy regimen.
The antihypertensive effect of trandolapril is obtained
with doses varying from 1.0mg to 8.0mg/day. Even with
relatively low doses such as 2.0mg/day, normalization or
satisfactory blood pressure reduction e.g. a 10mmHg
reduction in BP occurs in about 70% of patients, as de-
monstrated by many studies with distinct follow-up periods 2,3.
Furthermore, the antihypertensive efficacy of this
drug over placebo 2,4 and similar to that of many other
antihypertensive compounds 5 has been clearly demons-
trated by several studies.
Another important issue, considering that this drug,
as with many other ACE inhibitors, is given once a day, is to
ensure that blood pressure control is maintained throu-
ghout the 24 hour day.
The importance of the ambulatory blood pressure
monitoring (ABPM) in the evaluation of blood pressure
response to drug therapy is well known, especially in stu-
dying the effects of newer drugs in hypertensive patients.
Thus, the purpose of this study was to twofold: to
evaluate in a multicenter trial patients with mild-to-moderate
essential hypertension for tolerabillity to trandolapril and
the antihypertensive efficacy of trandolapril in comparison
with placebo as demonstrated by the reduction in office
blood pressure (study 1); and to evaluate in a subgroup of
patients, in a noncomparative manner, the duration of the
hypotensive effect of trandolapril using the ambulatory
blood pressure monitoring (ABPM) (study 2).
Methods
Study 1 - This study included 262 patients with mild-
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to-moderate essential hypertension (102 male and 160
female), age >25 years, from 34 different medical centers.
Exclusion criteria were presence of secondary forms
of hypertension, body mass index (BMI) >30kg/m2, serum
creatinin levels >1.5mg/dL, serum potassium levels > 5.5
mEq, and the presence of left ventricular hypertrophy in
the EKG. Patients with end-organ damage and/ or clinical
complications due to the hypertensive state were also not
admitted to the study. Women of childbearing potential not
using medically acceptable contraceptive methods, and
patients with systolic blood pressure levels >200mmHg or
diastolic levels over 115mmHg were also excluded from
this study.
The design of this study was randomized, double-
blind and placebo controlled. We enrolled patients who had
in the initial visit, diastolic blood pressure (DBP) levels
ranging from 95 to 115mmHg after undergoing a washout
period of two weeks with administration of placebo pills
once a day. Following that period, patients were randomized
into either a placebo (n=135) or trandolapril (n = 127) 2.0mg
regimen once a day for eight consecutive weeks. In addition
to blood pressure evaluation, serum creatinine and potas-
sium levels were also determined at the beginning of the
randomization period and at the end of the study.
Study 2 – In this study 30 patients with mild-to-mode-
rate essential hypertension from three different centers, 24
female and 6 male, age >18 years were included. Inclusion and
exclusion criteria were the same as for study 1.
This open-label study enrolled patients with DBP
varying from 95 to 115mmHg, in the initial visit After a two-
week washout period, trandolapril 2.0mg per day was
administered during 12 consecutive weeks. Blood pressure
readings were obtained during each visit to the clinic and at
the end of washout (week 0) and trandolapril treatment
(week 12) periods. All patients of this study had their blood
pressure evaluated by ambulatory blood pressure moni-
toring (ABPM).
In both studies the following data were obtained at the
initial visit: duration of the hypertension, smoking, drinking,
physical activity habits, previous use of antihypertensive
drugs and the presence of concomitant diseases. At each
visit to the clinic during the follow-up period, office blood
pressure levels, body weight and heart rate (HR) of all
patients were monitored, and a complete physical exami-
nation was also performed. Severity and duration of adverse
events related to the investigational drug were also recor-
ded at each visit.
For both studies, office blood pressure levels repre-
sent the mean of 3 consecutive readings using a mercury
sphygmomanometer and performed by the same investi-
gator after 5m at rest in a quiet environment, with the pa-
tient in a sitting position.. Phases I and V of Korotkoff
sounds were used for systolic (SBP) and diastolic (DBP)
measurements.
Blood pressure control was defined when office blood
pressure during treatment was lower than 140/90mmHg. If a
DBP reduction of 10mmHg compared with baseline was
achieved, despite not reaching normal levels, patients were
defined as responders.
In study 2, ABPM was performed with a Spacelabs
monitor, model 90207, recording blood pressure levels every
15m in the vigil period and every 20m in the sleep period.
The time of the day for beginning ABPM varied from
patient to patient; the vigil period included patient’s regular
activities (job, study, home care, meals, etc.) and the sleep
period was considered that from the time patients went to
bed to the hour of getting up the following morning. For
data analyses only those ABPM records showing BP of at
least 80% were accepeted.
Both studies were approved by local Ethics Com-
mittees and before study initiation an informed consent was
signed by each patient.
Results
Study 1 – Table I shows the demographic charac-
teristics of the study groups. There was a homogeneous
patient distribution in the placebo and trandolapril groups
and no statistically significant difference was observed
between the two groups for all demographic parameters
evaluated.
 Before study initiation, in the placebo group, 64
patients used one drug and 47 used two or more drugs.
Similarly, in the group treated with trandolapril, 55 used one
drug before starting the study and 46 used two or more
drugs. The most frequent concomitant diseases present in
both groups were: diabetes mellitus, obesity, dyslipidemia,
asthma and varicous veins.
There were no significant changes in clinical exami-
nation, body weight and HR alterations during the eight
week observation period (table II).
Serum creatinine levels were not different between the
two groups not only during the basal period (0.9±0.2 vs
0.9±0.22mg/dL, ns; placebo vs trandolapril group, respec-
tively) but also at the end of the study, 0.9±0.2mg/dL levels
for placebo group, and 0.87±0.2mg/dL, for trandolapril
group (ns). On the other hand, serum potassium levels that
were similar in the initial evaluation (4.2±0.4 vs 4.2±0.4mEq/
L; placebo and trandolapril, respectively) become slightly
greater at the end of treatment in the trandolapril group
(4.3±0.4 vs 4.2±0.4mEq/L, p<0.05).
Figures 1 and 2 show SBP and DBP values, respec-
tively, in both groups before and during therapy. At the end
of the washout period (placebo), the two groups showed
similar pressure values both for SBP (156.1±18 vs 157.3 ±
15mmHg, ns) and for DBP (100.3±6.6 vs 101±6.3mmHg, ns).
It was observed that both treatments determined gradual
BP reduction during the eight week evaluation period; this
effect was significantly greater with trandolapril when
compared with the placebo group. Thus, BP levels, both
SBP and DBP recorded at the end of the study were signifi-
cantly lower in the trandolapril group (143 ± 18/91 ± 9.8
mmHg), when compared with the placebo group (149 ± 19/9
e 4 ± 10.4mmHg, p<0.05).
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In addition, we observed that BP control (42% vs 27%,
p<0.05) and responder rates (16% vs 11%) were significan-
tly greater in the trandolapril group when compared with the
to placebo group. Therefore, antihypertensive efficacy was
significantly greater in the trandolapril group when compa-
red with the placebo group (57,5% vs 37.8%, p=0.002).
Regarding the presence of side effects, the most
prevalent adverse event in the placebo group was headache
(17%), and in the trandolapril group was cough (10%). Other
frequent adverse events in the placebo group were dizzi-
ness (6%), cough (4%), palpitations (4%) and weakness
(3%). In the trandolapril group headache (7%) and dizziness
(5%) were also reported.
Twelve patients from the placebo group and four from
the trandolapril group did not complete the study or were
considered lost in the follow-up.
Study 2 – Table I shows the characteristics of this
group of patients. We can observe that patients of this
study were very similar to those of study 1.
In this study, 13 patients had been using one drug and
the others had been using two or more drugs to previously
treat their hypertension. Diabetes mellitus, osteoarticular
diseases, hypothyroidism and varicous veins were the most
common concomitant diseases present in this group.
As in study 1, baseline and end-study levels of serum
creatinine were similar (0.87±0.2 vs 0.9±0.25mg/dL). In this
study, plasmatic potassium levels were similar in placebo
and trandolapril groups 4.5±0.45 and 4.5±0.52mEq/L).
Baseline and end-study body weight (65.7±15.3 vs 67.3 ±
10.8kg) and heart rate (75.4+11.1 vs 73.9+9.8 bpm) were also
not different.
Headache was the most frequent side effect (4 cases)
while only one patient had a cough complaint.
As in study 1 we observed in study 2 a statistically
significant reduction in pressure levels after 12 weeks of
treatment with trandolapril. Both ambulatory SBP and DBP
values were significantly reduced with trandolapril (161 ±
12/102.5 ± 5.5 vs 149 ± 14.3/93.6 ± 7.9mmHg, p<0.05, basal
and final, respectively). We also observed antihypertensive
efficacy rates, that is normalization and/or reduction of at
least 10mmHg of BP levels, similar to those obtained in
study 1.
Figures 3 and 4 represent the hourly averages of SBP
and DBP, respectively, obtained from ABPM of patients
considered responders to trandolapril at office BP records.
It was observed that trandolapril treatment brought about
significant reduction in BP, which were maintained 24h a
day, especially for SBP. The hypotensive effect was sligh-
tly greater in the vigil period when compared with the slee-
ping period.
Discussion
Results obtained in both studies show that trando-
lapril offers a satisfactory approach for BP reduction.
Our observations are in accordance with previous
noncomparative studies reporting SBP reduction from 6 to
15% and 8 to 17% for DBP 6,7. The efficacy of blood pres-
sure reduction in these studies was related to the obser-
vation period. In studies in which duration of follow up was
up to 12 months, the observed reductions reached 19% for
SBP, while for DBP no further reductions were observed 6.
In our studies, we observed that for both the 12 week
(three months) and the eight week (two months) obser-
vation periods, BP reductions for the trandolapril group
were 7.5% and 9% for SBP, and 8.2% and 10% in DBP,
supporting previous data in the literature.
Regarding the population characteristics, the drug
profile was adequate. This was a multicenter study, with
intake food patterns (salt ingestion) and ethnic charac-
Table II – Body weight and heart rate in placebo (n=135) and trandolapril group (n=127)
Week/Group -2 0 2 5 8
Weight (kg)
Placebo 68.9±9.9 69.0±9.80 69.2±9.9 69.1±10.2 69.0±10.2
Trandolapril 68.0±10.8 68.1±10.7 67.9±10.7 67.7±10.8 67.5±10.9
Heart rate  (bpm)
Placebo 75.1±9.5 75.7±9.85 76.3±9.7 76.6±10.4 76.4±9.3
Trandolapril 76.1±9.48 75.6±9.11 76.4±8.8 75.4±8.7 75.5±8.2
Table I – Demographic characteristics of patients in placebo and
trandolapril group (study 1) and trandolapril evaluated with
AMBP (study 2)
Study 1 Study 2
Placebo Trandolapril Trandolapril
(n=135) (n=127) (n=30)
Age (years) 53.1±11.3 53.0±11.6 56.3±10.7
Gender (M/F) 55/80 47/80 6/24
Ethnic group
White 64 71 12
Non white 58 50 16
Non referred 13 6 2
Smoking Y/N 24/111 9/118 2/28
Drinking Y/N 15/120 9/118 1/29
Physical activity
Y/N 49/86 49/78 12/18
History time (years) 9.4±8.2 8.7±8.3 11±7
Hypertension type
Mild/moderate 72/62 67/60 23/7
Non specified 1 - -
Previous drugs Y/N 111/24 101/26 25/5
Concomitant diseases
Y/N 41/94 39/88 13/17
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teristics from different regions of the country, which might
influence BP, mainly because of the decrease in the efficacy
of ACE inhibitors in nonwhite subjects or in those with a
high sodium intake.
However, our results showed that the efficacy of tran-
dolapril was similar in white and nonwhite subjects. Thus, we
observed that both BP reduction intensity and trandolapril-
responsive patients (about 58%) observed in nonwhite
patients (39% and 53% of patients in studies 1 and 2) were not
different from white patients. Thus, in our study, BP res-
ponse to conversion enzyme blockade with trandolapril was
uniform, not being influenced by ethnic differences.
Although we did not measure salt consumption in our
population, which should be very variable due to regional
habits, we did observe differences in our study, when re-
sults among study centers from different regions of the
country were compared.
Our results obtained through ABPM were in accor-
dance with previous studies showing that the antihy-
pertensive effect of trandolapril lasts 24h in those patients
considered responsive to this ACE inhibitor.
In spite of the fact the duration of the antihypertensive
effect of trandolapril, was evaluated in an open, non-
placebo controlled manner which partially diminishes its
statistical power, the results observed in study 2 are relevant
because they complement the information gathered in
study 1, corroborating previous observations of the
literature 5,6 and results obtained concomitantly to study 1 in
very similar populations.
In addition to being effective, trandolapril was shown
to be a drug with good tolerability, because adverse events
were not different from those observed with placebo use,
even with the loss of follow-up of a very small number of
patients. The side effect profile observed does not differ
Fig. 2 – Diastolic blood pressure before and during placebo (n=135) or trandolapril
(n=127) treatment.
Fig. 3 – Hourly average of systolic blood pressure recorded during AMBP before and
after 12-week treatment with trandolapril.
Figure 1 – Systolic blood pressure before and during placebo (n=135) or trando-
lapril (n=127) treatment.
Fig. 4 – Hourly average of diastolic blood pressure during AMBP before and after
12-week treatment with trandolapril.
Weeks Weeks
hours hours
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from those already described for trandolapril, as well as for
other ACE inhibitors.
In conclusion our data show that, similar to data from
other studies, trandolapril is an effective drug for blood
pressure control, regardless of the characteristics of the
study population, with a prolonged hypotensive effect and
very good tolerability.
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